Edesa Biotech Reports $7.2 Million Net Loss and Advances Clinical Pipeline

Edesa Biotech, Inc. reported a net loss of $7.2 million for the fiscal year ending September 30, 2025, compared to a net loss of $6.2 million for the previous year. The company's total operating expenses increased to $7.9 million from $7.0 million, primarily driven by a rise in research and development (R&D) costs, which reached $3.7 million, up from $2.9 million in 2024. This increase was attributed to heightened manufacturing-related activities and preparations for a planned Phase 2 clinical study of EB06, an anti-CXCL10 monoclonal antibody candidate for vitiligo, as well as ongoing studies for EB05, a treatment for Acute Respiratory Distress Syndrome (ARDS).

Edesa's financial position showed improvement, with cash and cash equivalents rising to $10.8 million at the end of September 2025, compared to $1.0 million a year earlier. The company has been actively raising capital, securing approximately $15 million from a private placement of Series B-1 Preferred Shares and additional funds through an at-the-market equity offering program. However, Edesa indicated that its current financial resources may not be sufficient to support operations through the end of fiscal 2026 without further capital raises or cost reductions.

In terms of strategic developments, Edesa is advancing its clinical pipeline, focusing on two therapeutic areas: Medical Dermatology and Respiratory. The company has received regulatory approval from Health Canada to conduct a Phase 2 study of EB06 and is in discussions with the U.S. Food and Drug Administration (FDA) for the same study, with plans to initiate enrollment by mid-2026. Additionally, EB05 has shown promising results in a truncated Phase 3 clinical study, meeting primary and secondary endpoints with statistical significance, which positions it favorably for further development.

Operationally, Edesa has a small workforce of 17 full-time employees, with a focus on R&D and management. The company is also benefiting from government support, having secured up to C$23 million in partially repayable funding from the Canadian government to support the development of EB05. Despite these advancements, Edesa faces significant risks, including the need for substantial additional funding to continue its operations and the inherent uncertainties associated with clinical trials and regulatory approvals. The company remains committed to exploring strategic partnerships and collaborations to enhance its development capabilities and market presence.